Leerink Partnrs Comments on Exact Sciences FY2026 Earnings

Exact Sciences Co. (NASDAQ:EXAS) – Investment analysts at Leerink Partnrs increased their FY2026 earnings per share (EPS) estimates for shares of Exact Sciences in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now expects that the medical research company will earn $0.81 per share for the year, up from their prior forecast of $0.80. The consensus estimate for Exact Sciences’ current full-year earnings is ($1.10) per share.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The business had revenue of $708.66 million during the quarter, compared to the consensus estimate of $716.80 million. Exact Sciences’s revenue for the quarter was up 12.8% on a year-over-year basis.

EXAS has been the subject of a number of other reports. BTIG Research upped their target price on Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Sanford C. Bernstein upped their target price on Exact Sciences from $75.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Evercore ISI cut their target price on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. William Blair restated an “outperform” rating on shares of Exact Sciences in a research report on Monday, January 13th. Finally, TD Cowen upped their target price on Exact Sciences from $82.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. One investment analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $72.76.

Exact Sciences Stock Performance

Shares of EXAS stock opened at $55.13 on Wednesday. The firm has a market capitalization of $10.20 billion, a price-to-earnings ratio of -47.12 and a beta of 1.24. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93. Exact Sciences has a 12-month low of $40.62 and a 12-month high of $79.62. The business has a 50 day simple moving average of $57.41 and a 200 day simple moving average of $59.32.

Insider Activity

In related news, CEO Kevin T. Conroy purchased 19,500 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were acquired at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the purchase, the chief executive officer now owns 1,074,191 shares of the company’s stock, valued at $55,159,707.85. The trade was a 1.85 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.36% of the company’s stock.

Hedge Funds Weigh In On Exact Sciences

Hedge funds have recently modified their holdings of the stock. Huntington National Bank increased its stake in shares of Exact Sciences by 838.1% in the third quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after acquiring an additional 352 shares during the last quarter. RPg Family Wealth Advisory LLC acquired a new position in shares of Exact Sciences in the third quarter worth $34,000. Capital Performance Advisors LLP acquired a new position in shares of Exact Sciences in the third quarter worth $35,000. Modus Advisors LLC acquired a new position in shares of Exact Sciences in the fourth quarter worth $43,000. Finally, Vestor Capital LLC acquired a new position in shares of Exact Sciences in the third quarter worth $46,000. 88.82% of the stock is owned by institutional investors and hedge funds.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.